Loading
A phase 3 trial of Zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Leucovorin (folinic acid) and Fluorouracil (5-FU) in gastric & gastro-oesophageal junction cancer, run by Astellas Pharma Global Development, Inc., now recruiting.
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer is a phase 3 interventional study registered as NCT06901531 by Astellas Pharma Global Development, Inc., with 500 participants planned, started 2025-05-22 and due to reach its primary completion in 2028-09-30. Interventions recorded: zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent) and 5-fluorouracil (5-FU).
Shares Zolbetuximab, Astellas, Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.
Shares Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Zolbetuximab, Astellas, Monoclonal antibodies and the tag pipeline.
Shares Leucovorin (folinic acid), Oxaliplatin, Capecitabine and the tag pipeline.